FDA Clears Path for Generic Rasuvo Methotrexate Copies
Published Date: 7/22/2026
Notice
Summary
The FDA has decided that RASUVO (methotrexate) solution wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and possibly cheaper for patients who need this medicine. If all rules are met, these generics could hit the market soon, helping more people get access without breaking the bank.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Approval Path Opens
The FDA determined on July 22, 2026 that RASUVO (methotrexate) solution, 27.5 mg/0.55 mL, was not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, abbreviated new drug applications (ANDAs) that refer to RASUVO may be approved if they meet all other legal and regulatory requirements, allowing generic manufacturers to seek approval.
Patients Could Pay Less and Get Easier Access
The FDA notice says generic versions of RASUVO could reach the market soon now that ANDAs may be approved; this could make it easier and possibly cheaper for patients who need methotrexate injections (RASUVO, 27.5 mg/0.55 mL) to get the medicine. Any generic entry depends on applicants meeting legal and regulatory requirements.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18333, Agency Information Collection Activities; Proposed Collection; Comment Request; Human Cells, Tissues, and Cellular and Tissue-Based Products
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed reinstatement of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection associated with statutory and regulatory requirements that govern certain human cells, tissues, and cellular and tissue-based products (HCT/Ps).
2026-18299, Agency Information Collection Activities; Proposed Collection; Comment Request; Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers To Advance Pregnancy Safety Data Collection and Improve Health Communications
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on a proposed study entitled "Pregnancy Exposure Registry Enrollment Project: A Survey of Health Care Providers to Advance Pregnancy Safety Data Collection and Improve Health Communications."
2026-18368, Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates; Guidance for Industry; Availability
The Food and Drug Administration (FDA, Agency, or we) is announcing the availability of a guidance for industry titled "Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates." This guidance describes the FDA's regulatory and enforcement priorities regarding the compounding of certain starter parenteral nutrition drug products for neonates by outsourcing facilities and by State-licensed pharmacies and Federal facilities that are not registered with FDA as outsourcing facilities. This guidance is being published for immediate implementation due to the expected market exit of the predominant source of certain starter parenteral nutrition drug products for neonates in the United States.
Previous / Next Documents
Previous: 2026-14778, Notice Pursuant to the National Cooperative Research and Production Act of 1993-Pistoia Alliance, Inc.
The Pistoia Alliance, a group working together on research, just added six new members from the US, Canada, the UK, the Netherlands, and an individual from Massachusetts. One member from Germany left the group. These changes keep the group’s special legal protections in place, and membership is still open for others who want to join.
Next: 2026-14780, Notice Pursuant to the National Cooperative Research and Production Act of 1993-Mobile Satellite Services Association
The Mobile Satellite Services Association (MSSA) just updated its team by adding Creative5 Inc. from Taiwan and saying goodbye to Simnovus Corporation from North Carolina. These changes keep the group’s special legal protections in place, helping members avoid big antitrust lawsuits except for actual damages. If you’re part of MSSA or thinking about joining, keep an eye out—membership is open and updates will keep coming!